NewsBenzingaReported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303 Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303 Benzinga 2026.11.20 05:38 (GMT+0) Open on Benzinga Other news Geospace Technologies (GEOS) Shares Tumble 16.47% After Hours: Here's Why Stock Market: Will S&P 500 Open Up or Down Today? Update: Geospace Technologies Q4 Adj. EPS $(0.86) Down From $(0.71) YoY, Sales $19.589M Down From $30.714M YoY Morning Bid: Anthropic's splashy IPO fails to lift AI boat Onfolio Holdings (ONFO) Stock Drops 16.80% After Hours: Here's What Investors Should Know Reported Earlier, Guardforce AI Class A Shares Will Trade Split-Adjusted Nov 24 After 1-For-40 Reverse Split Cuts Shares To ~799,233 From ~31.96M; CEO Wang Voting Power Rises To ~69% From ~10%
Update: Geospace Technologies Q4 Adj. EPS $(0.86) Down From $(0.71) YoY, Sales $19.589M Down From $30.714M YoY
Reported Earlier, Guardforce AI Class A Shares Will Trade Split-Adjusted Nov 24 After 1-For-40 Reverse Split Cuts Shares To ~799,233 From ~31.96M; CEO Wang Voting Power Rises To ~69% From ~10%